Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.


Active surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study of active surveillance.

We studied 905 men in the prospective Canary PASS enrolled between 2008 and 2013. We collected clinical data at study entry and at prespecified intervals, and determined associations with adverse reclassification, defined as increased Gleason grade or greater cancer volume on followup biopsy. We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active surveillance.

At a median followup of 28 months 24% of participants experienced adverse reclassification, of whom 53% underwent treatment while 31% continued on active surveillance. Overall 19% of participants received treatment, 68% with adverse reclassification, while 32% opted for treatment without disease reclassification. In multivariate Cox proportional hazards modeling the percent of biopsy cores with cancer, body mass index and prostate specific antigen density were associated with adverse reclassification (p=0.01, 0.04, 0.04, respectively). Of 103 participants subsequently treated with radical prostatectomy 34% had adverse pathology, defined as primary pattern 4-5 or nonorgan confined disease, including 2 with positive lymph nodes, with no significant relationship between risk category at diagnosis and findings at surgery (p=0.76).

Most men remain on active surveillance at 5 years without adverse reclassification or adverse pathology at surgery. However, clinical factors had only a modest association with disease reclassification, supporting the need for approaches that improve the prediction of this outcome.

  • Boyer HD
  • Brooks JD
  • Carroll PR
  • Cooperberg MR
  • Dash A
  • Ellis WJ
  • Fazli L
  • Feng Z
  • Gleave ME
  • Kunju P
  • Lance RS
  • Lin DW
  • McKenney JK
  • Meng MV
  • Nelson PS
  • Newcomb LF
  • Nicolas MM
  • Sanda MG
  • Simko J
  • So A
  • Thompson IM
  • Tretiakova MS
  • Troyer DA
  • True LD
  • Vakar-Lopez F
  • Virgin J
  • Wagner AA
  • Wei JT
  • Zheng Y
PubMed ID
Appears In
J Urol, 2016, 195 (2)